Recent international research has shown that the use of the AIDS drug “Truvada” in HIV-negative people is effective in preventing sexual transmission of the virus, but more research is needed to understand how this drug could be used in specific real-life contexts worldwide. Our researchers are running a pilot project in Antwerp with men who have sex with men to find out if preventive treatment is acceptable, can be taken safely and whether it can be integrated into existing prevention strategies.

HIV prevention with Pre-Exposure Prophylaxis (PrEP)

Principal investigator

• Marie Laga (Department of Public Health)

Co-promoters

• Chris Kenyon (Department of Clinical Sciences)
• Katrien Fransen (Department of Clinical Sciences)

IWT budget

• € 980,600

Key facts:

• The World Health Organization recommends using preventive HIV treatment in high-risk groups such as among men who have sex with men, but more research is needed to understand real-life implications.